DETAILS, FICTION AND CLINICAL EFFECTIVENESS OF ABBV-744 IN AML PATIENTS

In Section C, members will receive ABBV-744 and oral navitoclax. In Section D, contributors will obtain ABBV-744 and ruxolitinib. Members will get treatment until disorder progression or even the members are unable to tolerate the study drugs.after which endorse H3K27Ac at this region. Chromatin hyperacetylation could improve the accessibility with